Optimistic investors just saw a nice opportunity in Therapeutic Solutions International before the upcoming second wave of COVID-19. Recently, 500 volunteers took part in testing Quadramune (nutritional supplement). Until now results are unknown but OTC: TSOI suddenly shoots up by more than 200%.
Therapeutic Solutions International has a very tiny revenue that causes net loss all the time while positive results in developing products still deliver happiness on investors’ faces. For example, Quadramune reduced cells in a specific model of breast cancer. Such good news is key to maintain the company’s future projects that could raise more funds.
Currently, trading volume reaches up to 289,251,495 shares which are 15-folds greater than the average 17 million shares.